Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: Results from a phase 2a proof-of-concept study - 14/10/22
Key words : congenital ichthyosis, isotretinoin, retinoids, scaling, topical therapy
Funding sources: Supported by Patagonia Pharmaceuticals and a grant from the US Food and Drug Administration (1R01FD006079-01A1). |
|
IRB approval status: Reviewed and approved by the institutional review board of Schulman Associates IRB, Yale Human Investigation Committee (HIC), and Lurie Children's IRB. |
|
Reprints not available from the authors. |
Vol 87 - N° 5
P. 1189-1191 - novembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?